Literature DB >> 15269156

The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers.

Scott G Soltys1, Quynh-Thu Le, Gongyi Shi, Robert Tibshirani, A J Giaccia, Albert C Koong.   

Abstract

PURPOSE: Our study was undertaken to determine the utility of plasma proteomic profiling using surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry for the detection of head and neck squamous cell carcinomas (HNSCCs). EXPERIMENTAL
DESIGN: Pretreatment plasma samples from HNSCC patients or controls without known neoplastic disease were analyzed on the Protein Biology System IIc SELDI-TOF mass spectrometer (Ciphergen Biosystems, Fremont, CA). Proteomic spectra of mass:charge ratio (m/z) were generated by the application of plasma to immobilized metal-affinity-capture (IMAC) ProteinChip arrays activated with copper. A total of 37356 data points were generated for each sample. A training set of spectra from 56 cancer patients and 52 controls were applied to the "Lasso" technique to identify protein profiles that can distinguish cancer from noncancer, and cross-validation was used to determine test errors in this training set. The discovery pattern was then used to classify a separate masked test set of 57 cancer and 52 controls. In total, we analyzed the proteomic spectra of 113 cancer patients and 104 controls.
RESULTS: The Lasso approach identified 65 significant data points for the discrimination of normal from cancer profiles. The discriminatory pattern correctly identified 39 of 57 HNSCC patients and 40 of 52 noncancer controls in the masked test set. These results yielded a sensitivity of 68% and specificity of 73%. Subgroup analyses in the test set of four different demographic factors (age, gender, and cigarette and alcohol use) that can potentially confound the interpretation of the results suggest that this model tended to overpredict cancer in control smokers.
CONCLUSIONS: Plasma proteomic profiling with SELDI-TOF mass spectrometry provides moderate sensitivity and specificity in discriminating HNSCC. Further improvement and validation of this approach is needed to determine its usefulness in screening for this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269156     DOI: 10.1158/1078-0432.CCR-03-0469

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

Review 1.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

2.  SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis.

Authors:  Lei Cheng; Liang Zhou; Lei Tao; Ming Zhang; Jiefeng Cui; Yan Li
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

3.  EPO-KB: a searchable knowledge base of biomarker to protein links.

Authors:  Jonathan L Lustgarten; Chad Kimmel; Henrik Ryberg; William Hogan
Journal:  Bioinformatics       Date:  2008-04-09       Impact factor: 6.937

4.  Biomarkers of lupus nephritis determined by serial urine proteomics.

Authors:  Xiaolan Zhang; Ming Jin; Haifeng Wu; Tibor Nadasdy; Gyongyi Nadasdy; Nathan Harris; Kari Green-Church; Haikady Nagaraja; Daniel J Birmingham; Chack-Yung Yu; Lee A Hebert; Brad H Rovin
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

5.  The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.

Authors:  Amanda F Baker; Tomislav Dragovich; Wendy R Tate; Ramesh K Ramanathan; Denise Roe; Chiu-Hsieh Hsu; D Lynn Kirkpatrick; Garth Powis
Journal:  J Lab Clin Med       Date:  2006-02

6.  Promoter methylation in head and neck tumorigenesis.

Authors:  Josena K Stephen; Kang Mei Chen; Shaleta Havard; Glynis Harris; Maria J Worsham
Journal:  Methods Mol Biol       Date:  2012

Review 7.  Update on molecular diagnostic tests in head and neck cancer.

Authors:  Kevin T Palka; Robbert J Slebos; Christine H Chung
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

8.  MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment.

Authors:  Monika Pietrowska; Piotr Widłak
Journal:  Int J Proteomics       Date:  2012-07-30

9.  Alterations in cerebrospinal fluid proteins in a presymptomatic primary glioma model.

Authors:  John C Whitin; Taichang Jang; Milton Merchant; Tom T-S Yu; Kenneth Lau; Benjamin Recht; Harvey J Cohen; Lawrence Recht
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

10.  Serum peptidome variations in a healthy population: reference to identify cancer-specific peptides.

Authors:  Kun He; Xin-Yu Wen; Ai-Ling Li; Tao Li; Jie Wang; Hong-Xia Wang; Na Wang
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.